Wendy Zhong

Wendy Zhong

Auto-generated profile, based on publicly available information

Wendy Zhong

Analytical Research and Development, Merck & Co., Inc., Rahway, NJ, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2022 in Science
Verified
Journal Article
Closed access
AFAnna Fryszkowska
Anna Fryszkowska
CAChihui An
Chihui An
OAOscar Alvizo
Oscar Alvizo
GBGoutami Banerjee
Goutami Banerjee
KCKeith A. Canada
Keith A. Canada
WZWendy Zhong
Wendy Zhong
The emergence of new therapeutic modalities requires complementary tools for their efficient syntheses. Availability of methodologies for site-selective modification of biomolecules remains a long-standing challenge, given the inherent complexity and the presence of repeating residues that bear functional groups with similar reactivity profiles. We describe a bioconjugation strategy for modification of native peptides relying on high site selectivity conveyed by enzymes. We engineered penicillin G acylases to distinguish among free amino moieties of insulin (two at amino termini and an internal lysine) and manipulate cleavable phenylacetamide groups in a programmable manner to form protected insulin derivatives. This enables selective and specific chemical ligation to synthesize homogeneous bioconjugates, improving yield and purity compared to the existing methods, and generally opens avenues in the functionalization of native proteins to access biological probes or drugs.

19 February 2024 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
WCWai Ling Cheung‐Lee
Wai Ling Cheung‐Lee
JKJoshua N. Kolev
Joshua N. Kolev
JMJohn A. McIntosh
John A. McIntosh
AGAgnieszka A. Gil
Agnieszka A. Gil
WPWeilan Pan
Weilan Pan
KMKevin M. Maloney
Kevin M. Maloney

12 October 2022 in Analytica Chimica Acta
Verified
Journal Article
Closed access
DSDaniela Mesa Sanchez
Daniela Mesa Sanchez
HBHilary M. Brown
Hilary M. Brown
RYRuichuan Yin
Ruichuan Yin
BCBingming Chen
Bingming Chen
MVMarissa Vavrek
Marissa Vavrek
JLJulia Laskin
Julia Laskin

1 April 2017 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
HLHao Luoa
Hao Luoa
WZWendy Zhong
Wendy Zhong
JYJiong Yang
Jiong Yang
PZPing Zhuang
Ping Zhuang
FMFanyu Meng
Fanyu Meng
CWChristopher J. Welch
Christopher J. Welch

7 May 2026 in Science
Verified
Journal Article
Closed access
AKArtis Klapars
Artis Klapars
AFAnna Fryszkowska
Anna Fryszkowska
SGStephanie Galanie
Stephanie Galanie
OAOmer Ad
Omer Ad
EAEllen Y. Aguilera
Ellen Y. Aguilera
WZWendy Zhong
Wendy Zhong
Historically, many compelling therapeutic targets have been accessible only by injectable biologic drugs. Macrocyclic peptides, such as the proprotein convertase subtilisin/kexin type 9 inhibitor enlicitide for the treatment of atherosclerotic cardiovascular disease, are beginning to unlock these targets to orally administered therapies to enable broader patient access. We report the convergent biocatalytic assembly of enlicitide from simple building blocks enabled by a suite of engineered enzymes to catalyze selective peptide fragment formation, coupling, and macrocyclization in a protecting group–free manner. Together with efficient crystallizations that obviate the need for chromatography, this approach reduces the number of steps by greater than half compared with prior state-of-the-art methods, addressing long-standing synthetic challenges and offering a sustainable blueprint for the scalable development of complex peptide therapeutics.

1 July 2012 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
WZWendy Zhong
Wendy Zhong
XYXi Yang
Xi Yang
WTWeidong Tong
Weidong Tong
GMGary E. Martin
Gary E. Martin